SCHEMBL1834532

SCHEMBL1834532

Cc1ccc(Oc2ccccc2P(c2ccccc2Oc2ccc(C)cc2)c2ccccc2Oc2ccc(C)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.50
SLC6A4 P31645 2/20 0.50
LMNA P02545 2/20 0.49
ALDH1A1 P00352 6/20 0.47
HTT P42858 5/20 0.47
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TEAD4 Q15561 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
POLB P06746 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ATM Q13315 1/20 0.39
KDM4E B2RXH2 2/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1840334 0.89 HTR2A (0.45) HTR2ASLC6A4LMNAALDH1A1HTT
SCHEMBL1840257 0.83 LTA4H (0.50) SLC6A4LMNAALDH1A1HTTMAPK1
SCHEMBL2608310 0.83 HTT (0.65) HTR2ASLC6A4LMNAALDH1A1HTT
SCHEMBL6934511 0.81 RIPK1 (0.40) SLC6A4LMNAALDH1A1HTTMAPK1
SCHEMBL11585106 0.79 ALDH1A1 (0.60) HTR2ASLC6A4LMNAALDH1A1HTT
SCHEMBL2173690 0.77 HTR2A (0.40) HTR2ASLC6A4LMNAALDH1A1HTT
SCHEMBL172615 0.77 HTR2A (0.55) HTR2ASLC6A4LMNAALDH1A1HTT
SCHEMBL2023411 0.76 L3MBTL1 (0.41) HTR2ASLC6A4LMNAALDH1A1HTT
SCHEMBL29517257 0.75 TSHR (0.41) SLC6A4LMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL4833661 0.75 TSHR (0.41) SLC6A4LMNAALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321244-B1 IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-21 EP disclosed
US-8558030-B2 Process for telomerization of butadiene DOW GLOBAL TECHNOLOGIES LLC (US) 2013-10-15 US disclosed
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) 2011-06-09 US disclosed
EP-2321244-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (US) 2011-05-18 EP disclosed
WO-2010019360-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE HRH3, HRH4, TELO2 HTR2A 383/4885SLC6A4 4019/4885LMNA 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.